QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
CVE:LTY

Liberty Biopharma Stock Forecast, Price & News

C$2.00
+2.00 (+∞)
(As of 10/10/2018)
Add
Compare
Today's Range
C$2.00
▼
C$2.00
50-Day Range
C$2.00
▼
C$2.00
52-Week Range
C$0.06
▼
C$2.74
Volume700 shs
Average Volume23,286 shs
Market CapitalizationC$21.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive LTY News and Ratings via Email

Sign-up to receive the latest news and ratings for Liberty Biopharma and its competitors with MarketBeat's FREE daily newsletter.


About Liberty Biopharma

Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.

Headlines

Major U.S. insurers jump on distribution platforms to gain customers, sales
September 8, 2021 |  au.finance.yahoo.com
Liberty Expands to the Boston Area to Accelerate Company Growth
July 31, 2021 |  ca.finance.yahoo.com
Iraqi cleric Sadr says he won't take part in October election
July 16, 2021 |  au.finance.yahoo.com
Liberty Home Mortgage Grows Profitability, Increases Loan Volume by 53% with Lodasoft
April 14, 2021 |  au.finance.yahoo.com
LIBERTY Dental Plan of Oklahoma Awarded Oklahoma State Dental Benefits Administrator Contract
March 20, 2021 |  au.finance.yahoo.com
'Sun, sea, sand and Soberana 02': Cuba open to inoculating tourists with homegrown Covid vaccine
February 23, 2021 |  msn.com
Personal Money Store Available During Emergencies
January 21, 2021 |  benzinga.com
Small Cap Wrap - Westmount Energy; Remote Monitored Systems; Impax Asset Management; Destiny Pharma
January 6, 2021 |  proactiveinvestors.com
Regeneron Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
October 15, 2020 |  seekingalpha.com
BUZZ-U.S. STOCKS ON THE MOVE-Workday, Stable Road Acquisition, RedHill Biopharma, Fox Corp, Disney
October 9, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:LTY
Previous Symbol
CVE:VVA
CUSIP
N/A
CIK
N/A
Web
www.libertybiopharma.com
Phone
+1-604-3777575
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.00 per share
Price / Cash Flow
2,000.00
Book Value
C$0.79 per share
Price / Book
2.53

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
8.19
Current Ratio
0.12
Quick Ratio
0.12

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
10,770,000
Market Cap
C$21.54 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Liberty Biopharma (CVE:LTY) Frequently Asked Questions

What stocks does MarketBeat like better than Liberty Biopharma?

Wall Street analysts have given Liberty Biopharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Liberty Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Liberty Biopharma's key executives?

Liberty Biopharma's management team includes the following people:
  • Mr. Norman Tsui, Pres, CEO & Director (Age 45)
  • Mr. Shui Yan Tam, Chief Financial Officer (Age 44)
  • Dr. Michael T. McNamara, Medical Advisor & Director
  • Dr. Richard Huang Ph.D., Chief Technology Officer (Age 42)
  • Dr. Richard Cook M.D., Msc., FRCSC, Chief Medical Officer

What other stocks do shareholders of Liberty Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liberty Biopharma investors own include Brookfield Property Partners (BPY), Cross Timbers Royalty Trust (CRT), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), Brigham Minerals (MNRL), Arbor Realty Trust (ABR), Advanced Emissions Solutions (ADES), Archer-Daniels-Midland (ADM), AGNC Investment (AGNC) and AMC Entertainment (AMC).

What is Liberty Biopharma's stock symbol?

Liberty Biopharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LTY."

How do I buy shares of Liberty Biopharma?

Shares of LTY and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Liberty Biopharma's stock price today?

One share of LTY stock can currently be purchased for approximately C$2.00.

How much money does Liberty Biopharma make?

Liberty Biopharma has a market capitalization of C$21.54 million.

What is Liberty Biopharma's official website?

The official website for Liberty Biopharma is www.libertybiopharma.com.

Where are Liberty Biopharma's headquarters?

Liberty Biopharma is headquartered at 2270-8788 McKim Way, RICHMOND, BC V6X 4E2, Canada.

How can I contact Liberty Biopharma?

Liberty Biopharma's mailing address is 2270-8788 McKim Way, RICHMOND, BC V6X 4E2, Canada. The biotechnology company can be reached via phone at +1-604-3777575.


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.